跳至主要内容
临床试验/NCT01583738
NCT01583738已完成2 期

Effect of V0251 in Acute Vertigo

Pierre Fabre Medicament39 个研究点 分布在 5 个国家目标入组 132 人开始时间: 2012年4月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
2 期
状态
已完成
入组人数
132
试验地点
39
主要终点
"Vertigo Symptoms Score" (VSS) rated by patient using VAS

研究概览

简要总结

Assessment of efficacy and tolerance of a new anti-dizziness drug in acute vertigo.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围
18 Years 至 70 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Men or women
  • Age 18 to 70 years
  • Acute vertigo attack due to vestibular disorder

排除标准

  • Signs of brain, brainstem and/or cerebellar dysfunction
  • Concomitant central neurological disorder
  • Psychogenic vertigo
  • Use of ototoxic drugs causing vertigo or dizziness within the last month
  • Use of anti-dizziness medications from the onset of symptoms, except if the dosage had been stable for at least 3 months

研究组 & 干预措施

Placebo

Placebo Comparator

干预措施: placebo (Drug)

V0251

Experimental

干预措施: V0251 (Drug)

结局指标

主要结局

"Vertigo Symptoms Score" (VSS) rated by patient using VAS

时间窗: 30 min

次要结局

  • Number of patients with Adverse Events as a measure of safety and tolerability(30 min, 2 hours and 4 hours post dose)
  • "Concomitant and Vegetative Symptoms Score" (CVSS) rated by patients using VAS(30 min, 2 hours and 4 hours post dose)

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (39)

Loading locations...

相似试验